The similarity question for biologicals and non-biological complex drugs

Daan J A Crommelin, Vinod P. Shah, I. Klebovich, Scott E. McNeil, Vera Weinstein, Beat Flühmann, Stefan Mühlebach, Jon S B De Vlieger

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Abstract For small - low molecular weight - molecule medicines a robust regulatory system has evolved over the years. This system guarantees high and constant quality of our (generic) medicines. Pharmaceutical equivalence and bioequivalence assessment are the pillars under that system. But there are complex medicines where the question of equivalence is more challenging to answer. For biologicals the paradigm of similarity rather than equality (the emergence of 'biosimilars') was developed in the past decade. This has been a program where an evolutionary, science based approach has been chosen by the frontrunner regulatory body, the EMA, with a 'learn and confirm' character. In addition, there is another group of complex drugs, the non-biological complex drugs, NBCDs, where the generic paradigm can be challenged as well. The NBCDs are defined as: 1. consisting of a complex multitude of closely related structures; 2. the entire multitude is the active pharmaceutical ingredient; 3. the properties cannot be fully characterized by physicochemical analysis and 4. the consistent, tightly controlled manufacturing process is fundamental to reproduce the product. NBCDs encompass product families such as the glatiramoids, liposomes, iron-carbohydrate colloids and many candidates of the group of the upcoming nanoparticulate systems. Following the main principles of regulatory pathways for biologicals (with appropriate product-by-product adjustments), instead of that for small molecules, would be the more logical strategy for these NBCDs. The status and outstanding regulatory issues for biosimilars and NBCD-similars/follow on versions were discussed at a conference in Budapest, Hungary (October 2014) and this commentary touches upon the issues brought up in the presentations, deliberations and conclusions.

Original languageEnglish
Article number3239
Pages (from-to)10-17
Number of pages8
JournalEuropean Journal of Pharmaceutical Sciences
Volume76
DOIs
Publication statusPublished - Apr 23 2015

Fingerprint

Biosimilar Pharmaceuticals
Pharmaceutical Preparations
Generic Drugs
Therapeutic Equivalency
Hungary
Colloids
Liposomes
Iron
Molecular Weight
Carbohydrates

Keywords

  • Biologicals
  • Biosimilars
  • Glatiramoids
  • Iron-carbohydrate complexes
  • Liposomes
  • Nanomedicines
  • Non-biological complex drugs

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Crommelin, D. J. A., Shah, V. P., Klebovich, I., McNeil, S. E., Weinstein, V., Flühmann, B., ... De Vlieger, J. S. B. (2015). The similarity question for biologicals and non-biological complex drugs. European Journal of Pharmaceutical Sciences, 76, 10-17. [3239]. https://doi.org/10.1016/j.ejps.2015.04.010

The similarity question for biologicals and non-biological complex drugs. / Crommelin, Daan J A; Shah, Vinod P.; Klebovich, I.; McNeil, Scott E.; Weinstein, Vera; Flühmann, Beat; Mühlebach, Stefan; De Vlieger, Jon S B.

In: European Journal of Pharmaceutical Sciences, Vol. 76, 3239, 23.04.2015, p. 10-17.

Research output: Contribution to journalArticle

Crommelin, DJA, Shah, VP, Klebovich, I, McNeil, SE, Weinstein, V, Flühmann, B, Mühlebach, S & De Vlieger, JSB 2015, 'The similarity question for biologicals and non-biological complex drugs', European Journal of Pharmaceutical Sciences, vol. 76, 3239, pp. 10-17. https://doi.org/10.1016/j.ejps.2015.04.010
Crommelin, Daan J A ; Shah, Vinod P. ; Klebovich, I. ; McNeil, Scott E. ; Weinstein, Vera ; Flühmann, Beat ; Mühlebach, Stefan ; De Vlieger, Jon S B. / The similarity question for biologicals and non-biological complex drugs. In: European Journal of Pharmaceutical Sciences. 2015 ; Vol. 76. pp. 10-17.
@article{9532a8ca5af24720b1ce38a6bbfffed2,
title = "The similarity question for biologicals and non-biological complex drugs",
abstract = "Abstract For small - low molecular weight - molecule medicines a robust regulatory system has evolved over the years. This system guarantees high and constant quality of our (generic) medicines. Pharmaceutical equivalence and bioequivalence assessment are the pillars under that system. But there are complex medicines where the question of equivalence is more challenging to answer. For biologicals the paradigm of similarity rather than equality (the emergence of 'biosimilars') was developed in the past decade. This has been a program where an evolutionary, science based approach has been chosen by the frontrunner regulatory body, the EMA, with a 'learn and confirm' character. In addition, there is another group of complex drugs, the non-biological complex drugs, NBCDs, where the generic paradigm can be challenged as well. The NBCDs are defined as: 1. consisting of a complex multitude of closely related structures; 2. the entire multitude is the active pharmaceutical ingredient; 3. the properties cannot be fully characterized by physicochemical analysis and 4. the consistent, tightly controlled manufacturing process is fundamental to reproduce the product. NBCDs encompass product families such as the glatiramoids, liposomes, iron-carbohydrate colloids and many candidates of the group of the upcoming nanoparticulate systems. Following the main principles of regulatory pathways for biologicals (with appropriate product-by-product adjustments), instead of that for small molecules, would be the more logical strategy for these NBCDs. The status and outstanding regulatory issues for biosimilars and NBCD-similars/follow on versions were discussed at a conference in Budapest, Hungary (October 2014) and this commentary touches upon the issues brought up in the presentations, deliberations and conclusions.",
keywords = "Biologicals, Biosimilars, Glatiramoids, Iron-carbohydrate complexes, Liposomes, Nanomedicines, Non-biological complex drugs",
author = "Crommelin, {Daan J A} and Shah, {Vinod P.} and I. Klebovich and McNeil, {Scott E.} and Vera Weinstein and Beat Fl{\"u}hmann and Stefan M{\"u}hlebach and {De Vlieger}, {Jon S B}",
year = "2015",
month = "4",
day = "23",
doi = "10.1016/j.ejps.2015.04.010",
language = "English",
volume = "76",
pages = "10--17",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - The similarity question for biologicals and non-biological complex drugs

AU - Crommelin, Daan J A

AU - Shah, Vinod P.

AU - Klebovich, I.

AU - McNeil, Scott E.

AU - Weinstein, Vera

AU - Flühmann, Beat

AU - Mühlebach, Stefan

AU - De Vlieger, Jon S B

PY - 2015/4/23

Y1 - 2015/4/23

N2 - Abstract For small - low molecular weight - molecule medicines a robust regulatory system has evolved over the years. This system guarantees high and constant quality of our (generic) medicines. Pharmaceutical equivalence and bioequivalence assessment are the pillars under that system. But there are complex medicines where the question of equivalence is more challenging to answer. For biologicals the paradigm of similarity rather than equality (the emergence of 'biosimilars') was developed in the past decade. This has been a program where an evolutionary, science based approach has been chosen by the frontrunner regulatory body, the EMA, with a 'learn and confirm' character. In addition, there is another group of complex drugs, the non-biological complex drugs, NBCDs, where the generic paradigm can be challenged as well. The NBCDs are defined as: 1. consisting of a complex multitude of closely related structures; 2. the entire multitude is the active pharmaceutical ingredient; 3. the properties cannot be fully characterized by physicochemical analysis and 4. the consistent, tightly controlled manufacturing process is fundamental to reproduce the product. NBCDs encompass product families such as the glatiramoids, liposomes, iron-carbohydrate colloids and many candidates of the group of the upcoming nanoparticulate systems. Following the main principles of regulatory pathways for biologicals (with appropriate product-by-product adjustments), instead of that for small molecules, would be the more logical strategy for these NBCDs. The status and outstanding regulatory issues for biosimilars and NBCD-similars/follow on versions were discussed at a conference in Budapest, Hungary (October 2014) and this commentary touches upon the issues brought up in the presentations, deliberations and conclusions.

AB - Abstract For small - low molecular weight - molecule medicines a robust regulatory system has evolved over the years. This system guarantees high and constant quality of our (generic) medicines. Pharmaceutical equivalence and bioequivalence assessment are the pillars under that system. But there are complex medicines where the question of equivalence is more challenging to answer. For biologicals the paradigm of similarity rather than equality (the emergence of 'biosimilars') was developed in the past decade. This has been a program where an evolutionary, science based approach has been chosen by the frontrunner regulatory body, the EMA, with a 'learn and confirm' character. In addition, there is another group of complex drugs, the non-biological complex drugs, NBCDs, where the generic paradigm can be challenged as well. The NBCDs are defined as: 1. consisting of a complex multitude of closely related structures; 2. the entire multitude is the active pharmaceutical ingredient; 3. the properties cannot be fully characterized by physicochemical analysis and 4. the consistent, tightly controlled manufacturing process is fundamental to reproduce the product. NBCDs encompass product families such as the glatiramoids, liposomes, iron-carbohydrate colloids and many candidates of the group of the upcoming nanoparticulate systems. Following the main principles of regulatory pathways for biologicals (with appropriate product-by-product adjustments), instead of that for small molecules, would be the more logical strategy for these NBCDs. The status and outstanding regulatory issues for biosimilars and NBCD-similars/follow on versions were discussed at a conference in Budapest, Hungary (October 2014) and this commentary touches upon the issues brought up in the presentations, deliberations and conclusions.

KW - Biologicals

KW - Biosimilars

KW - Glatiramoids

KW - Iron-carbohydrate complexes

KW - Liposomes

KW - Nanomedicines

KW - Non-biological complex drugs

UR - http://www.scopus.com/inward/record.url?scp=84929094956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929094956&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2015.04.010

DO - 10.1016/j.ejps.2015.04.010

M3 - Article

VL - 76

SP - 10

EP - 17

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

M1 - 3239

ER -